PH284 nasal spray increased hunger in cancer cachexia patients, showing a 71% improvement in subjective hunger scores compared to baseline. The phase 2A study demonstrated PH284's safety, with no ...

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no ...

The high prevalence of sarcopenia in patients with ovarian and endometrial cancers underscores the importance of early ...

Two new composition of matter patents granted in the US and Europe Patents provide protection relating to lead compound S-pindolol benzoate ...

and tolerability of intranasal administration of PH284 in female patients diagnosed with cachexia due to terminal cancer. PH284 nasal spray was administered intranasally, one spray in each nostril ...

and tolerability of intranasal administration of PH284 in female patients diagnosed with cachexia (induced by chronic loss of appetite) due to terminal cancer (n=40). PH284 nasal spray (0.4 µg/50 ...

Actimed Therapeutics’ anti-catabolic and pro-anabolic transforming agent, S-pindolol benzoate receives US & European patents: London, UK Friday, February 7, 2025, 16:00 Hrs [IST ...

The impact of cancer cachexia on patients and the urgent need for new treatments has become increasingly apparent, and we continue to press ahead with our plans to bring our potential new therapy ...